Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor
作者： Mark G. Kris , Mark G. Kris , Gregory J. Riely , Gregory J. Riely , Helena A. Yu
DOI: 10.1200/PO.20.00315
关键词:
摘要: PURPOSEInhibition of the MEK/ERK pathway is critical for Bcl-2-like protein 11 (BIM)-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-induced apoptosis, and dysregul...
sci-hub.st 参考文章(0)